MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

BAY1125976

CAS No. : 1402608-02-9

MCE 国际站：BAY1125976

产品活性：BAY1125976 是 Akt1/Akt2 选择性的变构抑制剂；在10 μM ATP 时抑制 Akt1 和 Akt2 活性的 IC₅₀值分别为 5.2 nM 和 18 nM。

研究领域：PI3K/Akt/mTOR

作用靶点：Akt

In Vitro: BAY 1125976 is equally potent against Akt1 (IC₅₀=5.2 nM at 10 μM ATP and 44 nM at 2 mM ATP) and Akt2 (IC₅₀=18 nM at 10 μM ATP and 36 nM at 2 mM ATP) isoforms and up to 86 fold less potent against Akt3 (IC₅₀=427 nM at 10 μM ATP). It inhibits the Akt1 and Akt2 by binding into an allosteric binding pocket formed by kinase and PH domain. It inhibits cell proliferation in a broad panel of human cancer cell lines, particularly in breast and prostate cancer cell lines expressing estrogen or androgen receptors. It effectively blocks Akt signaling by inhibiting the phosphorylation of Akt and the downstream effectors, including eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), glycogen synthase kinase 3 beta (GSK3s), proline-rich Akt substrate 40 kDa (PRAS40), S6 ribosomal protein (S6RP), and 70 kDa ribosomal protein S6 kinase 1 (70S6K).

In Vivo: BAY 1125976 targets tumors displaying activation of the PI3K/Akt/mTOR pathway. BAY 1125976 exhibits strong in vivo efficacy in both cell line and patient-derived xenograft models such as the KPL4 breast cancer model (PIK3CA^H1074R mutant), the MCF7 and HBCx-2 breast cancer models, and the Akt^E17K mutant driven prostate cancer (LAPC-4) and anal cancer (AXF 984) models.

相关产品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Chemical Probe Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Glucose Metabolism Compound Library  |  Targeted Diversity Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Highly Selective Inhibitors Library  |  LM22B-10  |  Insulin Detemir  |  (rac)-AG-205  |  Multi-kinase-IN-2  |  Akt/SKG Substrate Peptide  |  AS1949490  |  1,3-Dicaffeoylquinic acid  |  Threo-Chloramphenicol-d₆  |  AKT-IN-14  |  NSC45586  |  APN/AKT-IN-1  |  MS5033  |  Sophocarpine monohydrate  |  MS143  |  Deferoxamine  |  Chaetominine  |  Hu7691 free base  |  AKT-IN-3  |  8-Aminoadenosine  |  Nrf2/HO-1 activator 2  |  AT13148  |  Pachymic acid  |  Polygalasaponin F  |  Akt1&PKA-IN-1  |  Triciribine  |  PI3K-IN-29  |  Oxaprozin  |  CCT128930  |  YS-49

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。